The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Functional Selectivity and Biased Receptor Signaling
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Energy Landscapes and Motions of Proteins
Frauenfelder, H., Sligar, S. G., & Wolynes, P. G. (1991) · Science · doi:10.1126/science.1749933 · Cited by 3,250
A MODIFICATION OF RECEPTOR THEORY
STEPHENSON, R. P. (1956) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1956.tb00006.x · Cited by 1,156
Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“For example, if the second messenger can confidently be linked to therapeutic effect (i.e., insulin release and glucagon-like peptide-1 receptor agonism via elevation of cAMP; Kim and Egan, 2008) or if therapeutically relevant primary cells can be used in a labelfree assay screen, then these factors would need to be c…”
BackgroundWei, H., Ahn, S., Shenoy, S. K., Karnik, S. S., Hunyady, L., Luttrell, L. M., & Lefkowitz, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834556100 · Cited by 690
Agonist-receptor efficacy II: agonist trafficking of receptor signals
Kenakin, T. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89032-x · Cited by 657
Self-citationThe Thyrotropin Receptor and the Regulation of Thyrocyte Function and Growth*
VASSART, G., & DUMONT, J. E. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-3-596 · Cited by 644
Morphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 626
β-Arrestin-biased ligands at seven-transmembrane receptors
Violin, J. D., & Lefkowitz, R. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.006 · Cited by 606
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707936104 · Cited by 597
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Self-citationAzzi, M., Charest, P. G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., & Piñeyro, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1936664100 · Cited by 523
Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 510
Molecular mechanisms of membrane receptor desensitization
Lohse, M. J. (1993) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(93)90139-g · Cited by 436
Lawler, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 408
Resonant Waveguide Grating Biosensor for Living Cell Sensing
Fang, Y., Ferrie, A. M., Fontaine, N. H., Mauro, J., & Balakrishnan, J. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.077818 · Cited by 383
Violin, J. D., DeWire, S. M., Yamashita, D., Rominger, D. H., Nguyen, L., Schiller, K., Whalen, E. J., Gowen, M., & Lark, M. W. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173005 · Cited by 370
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.004 · Cited by 363
Ligand-selective receptor conformations revisited: the promise and the problem
Kenakin, T. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00167-6 · Cited by 321
Self-citationNew Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism
Kenakin, T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1875 · Cited by 317
Self-citationTobin, A. B., Butcher, A. J., & Kong, K. C. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.006 · Cited by 308
Galandrin, S., & Bouvier, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026716 · Cited by 291
Zidar, D. A., Violin, J. D., Whalen, E. J., & Lefkowitz, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904361106 · Cited by 278
Schröder, R., Janssen, N., Schmidt, J., Kebig, A., Merten, N., Hennen, S., Müller, A., Blättermann, S., Mohr-Andrä, M., Zahn, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1671 · Cited by 256
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J., & Lefkowitz, R. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36806 · Cited by 240
Multiple Signaling States of G-Protein-Coupled Receptors
Perez, D. M., & Karnik, S. S. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.2 · Cited by 237
Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Schmid, C. L., Raehal, K. M., & Bohn, L. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708862105 · Cited by 229
Ménard, L., Ferguson, S. S. G., Zhang, J., Lin, F.-T., Lefkowitz, R. J., Caron, M. G., & Barak, L. S. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.800 · Cited by 228
Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., & Bohn, L. M. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.028258 · Cited by 224
Rajagopal, K., Whalen, E. J., Violin, J. D., Stiber, J. A., Rosenberg, P. B., Premont, R. T., Coffman, T. M., Rockman, H. A., & Lefkowitz, R. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607583103 · Cited by 214
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Kenakin, T. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.2 · Cited by 213
Self-citationGPCR functional selectivity has therapeutic impact
Mailman, R. B. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.002 · Cited by 208
Gesty-Palmer, D., Flannery, P., Yuan, L., Corsino, L., Spurney, R., Lefkowitz, R. J., & Luttrell, L. M. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000071 · Cited by 205
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197
A Statistical Thermodynamic Model of the Protein Ensemble
Hilser, V. J., García-Moreno E., B., Oas, T. G., Kapp, G., & Whitten, S. T. (2006) · Chemical Reviews · doi:10.1021/cr040423+ · Cited by 187
Willins, D. L., Berry, S. A., Alsayegh, L., Backstrom, J. R., Sanders-Bush, E., Friedman, L., & Roth, B. L. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00653-8 · Cited by 171
Zhai, P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25330 · Cited by 171
Ji, S., Zhang, Y., Cleemput, J. V., Jiang, W., Liao, M., Li, L., Wan, Q., Backstrom, J. R., & Zhang, X. (2006) · Nature Medicine · doi:10.1038/nm1349 · Cited by 169
Analysis of Allosterism in Functional Assays
Ehlert, F. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090886 · Cited by 168
Violin, J. D., Ren, X.-R., & Lefkowitz, R. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513605200 · Cited by 148
Multiple mechanisms of serotonergic signal transduction
Roth, B. L., & Chuang, D. M. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90621-7 · Cited by 148
Bone Response to Intermittent Parathyroid Hormone Is Altered in Mice Null for β-Arrestin2
Ferrari, S., Pierroz, D. D., Glatt, V., Goddard, D. S., Bianchi, E. N., Lin, F., Manen, D., & Bouxsein, M. (2005) · Endocrinology · doi:10.1210/en.2004-1282 · Cited by 143
‘7TM Receptor Allostery: Putting Numbers to Shapeshifting Proteins
Kenakin, T. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.007 · Cited by 129
Self-citationMottola, D. M., Kilts, J. D., Lewis, M. M., Connery, H. S., Walker, Q. D., Jones, S. R., Booth, R. G., Hyslop, D. K., Piercey, M., Wightman, R. M., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1166 · Cited by 123
Peters, M. F., & Scott, C. W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108330115 · Cited by 121
Physiological and pharmacological implications of beta-arrestin regulation
Schmid, C. L., & Bohn, L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.005 · Cited by 103
When 7 transmembrane receptors are not G protein-coupled receptors
Rajagopal, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26950 · Cited by 101
Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors
Richman, J. G., Kanemitsu-Parks, M., Gaidarov, I., Cameron, J. S., Griffin, P. S., Zheng, H., Guerra, N. C., Cham, L., Maciejewski-Lenoir, D., Behan, D. P., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701866200 · Cited by 97
Conformational changes and drug action.
Burgen, A. S. (1981) · PubMed · Cited by 90
Peleg, G., Ghanouni, P., Kobilka, B. K., & Zare, R. N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151239698 · Cited by 88
Philip, F., Sengupta, P., & Scarlata, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701558200 · Cited by 87
Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance
Bosier, B., & Hermans, E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.001 · Cited by 62
Molecular determinants of angiotensin II type 1 receptor functional selectivity
Aplin, M., Bonde, M. M., & Hansen, J. L. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.09.123 · Cited by 58
Onaran, H., Scheer, A., Cotecchia, S., & Costa, T. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57081-0_9 · Cited by 54
Ryman-Rasmussen, J. P., Griffith, A. R., Oloff, S., Vaidehi, N., Brown, J. T., Goddard, W. A., & Mailman, R. B. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.028 · Cited by 52
A unique mechanism of -blocker action: Carvedilol stimulates -arrestin signaling
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Cited by 52
Pharmacological Onomastics: What's in a name?
Kenakin, T. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707407 · Cited by 51
Self-citationBeta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?
Metra, M., Cas, L. D., Lenarda, A. D., & Poole-Wilson, P. A. (2004) · Heart Failure Reviews · doi:10.1023/b:hrev.0000046367.99002.a4 · Cited by 51
Agonist-specific regulation of the δ-opioid receptor
Varga, E. V., Navratilova, E., Stropova, D., et al. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.07.020 · Cited by 41
Tran, J. A., Chang, A. L., Matsui, M., & Ehlert, F. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.051276 · Cited by 40
Cited by
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
Self-citationStructural Features for Functional Selectivity at Serotonin Receptors
Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X.-P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., et al. (2013) · Science · doi:10.1126/science.1232808 · Cited by 664
Metadata
- Authors
- Kenakin, T.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 336
- Issue
- 2
- Pages
- 296-302
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2138325877
- Cited by
- 505
- References
- 60
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.